ClinicalTrials.gg
Active, not recruitingNCT04809168Updated Nov 4, 2026

Neuropathic Spinal Pain in Ankylosing Spondylitis

An observational study in Ankylosing Spondylitis, sponsored by Bozyaka Training and Research Hospital. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Bozyaka Training and Research Hospital · Observational

How we know

Updated Nov 4, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
292
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 84 studies in Spondylitis, Ankylosing with a site in Turkey — 19 open to participants now, 21 under way, none of them phase 3. Spondylitis, Ankylosing · Turkey.

Enrollment
4th of 35
292 · median 100
Started
2021
with 9 others
Observational
35 of 84
7 open now
Primary completion
2024-11
later than 3 of 20 live
Registered
33rd of 84
by date
Lead sponsor
3 of 84
Bozyaka Training and Research Hospital

Among the 84 studies in Spondylitis, Ankylosing with a site in Turkey, this one is the 4th largest by enrollment of the 35 observational ones that give a count, is one of 10 that started in 2021, is one of 35 observational ones, reaches primary completion later than 3 of the 20 other live ones, and was the 33rd registered.

Spondylitis, Ankylosing

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 84 studies in Spondylitis, Ankylosing with a site in Turkey are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Spondylitis, Ankylosing with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this study is to investigate prevalence of neuropathic spinal pain in AS patients and it's impact on sleep quality. Moreover effects of neuropathic pain on quality of life and fatigue will be assessed.

Read the detailed description

Ankylosing spondylitis (AS) is a chronic, inflammatory rheumatic disease that mainly presenting with chronic back pain. In general, chronic low back pain is currently defined as a mixed pain including nociceptive and neuropathic properties. Nociceptive pain in several rheumatic diseases displays neuropathic characteristics over time. Patients with AS are suffered from spinal, entheseal pain or pain originated from peripheral and root joints. Although being scarce, there are trials investigating and reporting neuropathic component of spinal pain in axial spondyloarthritis/ankylosing spondylitis patients. However these trials either are not controlled or did not specify painful region of interest. In a few controlled trials control subjects were not defined clearly.

Sleep problems are reported to be prevalent among patients with chronic pain conditions such as inflammatory rheumatic diseases and fibromyalgia. In patients with ankylosing spondylitis sleep disturbance is a well defined issue. The fact that sleep problem is a common problem in AS, raises the need to explore it's associates. In the trials measuring spinal neuropathic pain, sleep disturbances and it's association with neuropathic pain were not assessed.

So, investigators have aimed to investigate prevalence of neuropathic spinal pain in AS patients and it's impact on sleep quality. For this purpose a case-control study design was planned. Age- and sex-matched control subjects will be chosen among individuals submitted to out-patient clinic with nociceptive/mechanical pain complaint lasting more than three months. Participants in control group will be subjected to same exclusion criteria too.

This design will allow the investigators to determine whether spinal pain in AS patients displays neuropathic character more frequently than any chronic nociceptive pain does.

03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

AS patients and age- and sex-matched control subjects will be chosen among individuals submitting to our out-patient clinic with nociceptive/mechanical pain complaint lasting more than three months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being diagnosed with AS according to the 1984 Modified New York Criteria
  • Visual Analogue Scale (VAS) spinal pain score ≥ 2

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus, renal insufficiency, hypothyroidism
  • Carpal tunnel syndrome, postherpetic neuralgia, spinal cord compression
  • Neurological diseases leading to neuropathic pain
  • Cervical and lumbar radiculopathy
  • Fibromyalgia
  • Severe cardiac disease
  • Pregnancy
  • Muscle weakness or hypoesthesia indicating peripheral nerve injury
  • In the last three months medical treatment leading to neuropathy (colchicine etc.)
  • In the last three months drug use for the treatment of fibromyalgia, depression and anxiety
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
292 participants (actual)
Patient registry
No

Groups and cohorts

  • AS patients

    AS patients diagnosed according to the modified New York criteria

    Other: Questionnaires and inventories

  • Control

    Age- and sex-matched control subjects with nociceptive/mechanical pain complaint lasting more than three months

    Other: Questionnaires and inventories

Interventions

  • OtherQuestionnaires and inventories

    questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.

    Also known as: physical examination

06

What researchers measure

Primary outcomes

  1. Neuropathic pain

    It will be assessed using the PainDETECT questionnaire. This questionnaire contains nine questions all of which are self-report. Seven items are rated on a six point Likert scale and thus are scored between 0-5. These seven questions query some sensations such as burning, tingling or prickling, allodynia, numbness etc. Apart from these seven items, one item assesses the radiation of pain and the other one item looks for the temporal characteristics of pain. A total score of 12 or less indicates neuropathic component is unlikely, 13-18 means possible neuropathic component and 19 or greater means a neuropathic component is likely. Beside these, there are three items in a separate section measuring severity of pain at the time of evaluation, on average and maximum over the past month. This section is not taken into account in scoring

    Time frame: Once, at baseline

  2. Sleep quality

    It will be assessed using Pittsburgh Sleep Quality Index (PSQI). It was developed by Buysse and coworkers in 1989. This index measures sleep quality quantitatively and covers 24 questions. Nineteen questions are self-rated and scoring is based on these self-rated questions, other five questions that rating by partner are not taken into account while calculating total score. Questionnaire measures seven domains; subjective sleep quality (question 6), sleep latency (question 2 and 5a), sleep duration (question 4), habitual sleep efficiency (question 1,3,4), sleep disturbances (question 5b-j), use of sleep medication (question 7), and daytime dysfunction (question 8 and 9) over the last month. Seven domain scores give a result on a 0 to 3 scale. To yield a total score the domain scores are summed. Total score varies between 0 and 21. Higher scores indicate worse sleep quality.

    Time frame: Once, at baseline

Secondary outcomes

  1. Health related quality of life

    Health related quality of life will be assessed using (Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) querying symptoms, functioning, and disease-related concern. It covers 18 dichotomous questions that ask participants to answer in a yes or no fashion. An answer of "yes" is assumed as one point. To get a final score, all points are summed. Thus, total score is between 0-18 and higher scores indicate worse quality of life.

    Time frame: Once, at baseline

  2. Fatigue

    It will be assessed using Fatigue Severity Scale. This scale contains nine questions and measures fatigue severity during the past week. Each question is rated between 1 (strongly disagree)-7 (strongly disagree). Total score is mean of all To calculate total score first the points of all answers are summed and then the result is divided by nine. Higher scores indicate severe fatigue

    Time frame: Once, at baseline

07

Study locations

1 site
  • Izmir Bozyaka Training and Research Hospital
    Izmir, Turkey (Türkiye)
08

References and documents

Publications

  • Aydin E, Bayraktar K, Turan Y, Omurlu I, Tastaban E, Sendur OF. [Sleep quality in patients with ankylosing spondylitis]. Rev Bras Reumatol. 2015 Jul-Aug;55(4):340-5. doi: 10.1016/j.rbr.2014.12.007. Epub 2015 Feb 9. Portuguese. PubMed 25772656 ↗
  • Geler-Kulcu D, Batibay S, Ozturk G, Mesci N. The association of neuropathic pain and disease activity, functional level, and quality of life in patients with ankylosing spondylitis: a cross-sectional study. Turk J Med Sci. 2018 Apr 30;48(2):257-265. doi: 10.3906/sag-1707-147. PubMed 29714437 ↗
  • Choi JH, Lee SH, Kim HR, Lee KA. Association of neuropathic-like pain characteristics with clinical and radiographic features in patients with ankylosing spondylitis. Clin Rheumatol. 2018 Nov;37(11):3077-3086. doi: 10.1007/s10067-018-4125-z. Epub 2018 Apr 30. PubMed 29713968 ↗
  • Wu Q, Inman RD, Davis KD. Neuropathic pain in ankylosing spondylitis: a psychophysics and brain imaging study. Arthritis Rheum. 2013 Jun;65(6):1494-503. doi: 10.1002/art.37920. PubMed 23460087 ↗
  • Li Y, Zhang S, Zhu J, Du X, Huang F. Sleep disturbances are associated with increased pain, disease activity, depression, and anxiety in ankylosing spondylitis: a case-control study. Arthritis Res Ther. 2012 Oct 11;14(5):R215. doi: 10.1186/ar4054. PubMed 23058191 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2021 to primary completion in Nov 2024, 42 months.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → May 2027, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Mar 22, 2021
StartActual
Apr 6, 2021
Primary completionActual
Nov 2, 2024
CompletionEst.
May 2, 2027was Dec 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Dec 2, 2026→May 2, 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Study completion Dec 2, 2026→May 2, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04809168
Lead sponsor
Bozyaka Training and Research Hospital
Responsible party
Taciser Kaya (Associate professor, MD, Bozyaka Training and Research Hospital) — Principal investigator
First posted
Mar 22, 2021
Start date
Apr 6, 2021
Primary completion
Nov 2, 2024
Completion
May 2, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Taciser Kaya
study director · Izmir Bozyaka Training and Reseach Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion